文献速递胸部介入CT

原发性与转移性肺部恶性肿瘤:肿瘤<4 cm与≥4 cm的CT引导高剂量率近距离消融(CT-HDRBT)回顾性分析

Primary and metastatic malignancies of the lung: Retrospective analysis of the CT-guided high-dose rate brachytherapy (CT-HDRBT) ablation in tumours <4 cm and ≥4 cm.
PubMed 文献 · Eur J Radiol · 2018-10-10

回顾性分析74例患者175个肺部肿瘤(132次介入),比较<4 cm(A组)与≥4 cm(B组)CT-HDRBT的疗效与安全性。A组局部肿瘤控制率和总生存率更高(5年LTC 46% vs 32%,OS 19% vs 0%),但B组仍安全可行,未出现出血,气胸16.6%,轻度放射性纤维化48.5%。

要点

  • CT-HDRBT对<4 cm肺部肿瘤的5年局部控制率46%、总生存率19%,优于≥4 cm肿瘤的32%和0%。
  • ≥4 cm肿瘤仍可安全行CT-HDRBT,未出现出血,气胸发生率16.6%,轻度放射性纤维化48.5%。
  • 处方剂量覆盖方面两组无统计学差异(p=0.263),但≥4 cm组覆盖均值94.81%±7.19%。

核心结论

  • CT-HDRBT在<4 cm原发性肺癌中观察到更高的局部肿瘤控制和总生存,但即使对≥4 cm肿瘤也是安全可行的替代治疗。

研究设计与样本

  • 回顾性研究,纳入2003年10月至2016年9月间74例连续患者(平均年龄63±12岁,男39例、女35例),共175个肿瘤、132次介入,按肿瘤<4 cm(A组)与≥4 cm(B组)分组,采用Kaplan-Meier法分析局部肿瘤控制、无进展生存和总生存,统计方法为Log-Rank检验和Mann-Whitney-U检验,p<0.05为显著。

诊断标准与关键数值

  • A组处方剂量覆盖长度19.78±8.62 mm(范围5-39 mm)、覆盖率99.56±0.99%;B组覆盖长度61.70±21.09 mm(范围41-100 mm)、覆盖率94.81±7.19%,两组覆盖率差异p=0.263。

临床应用与阅片要点

  • 作者认为CT-HDRBT是安全可行的替代治疗,即使对≥4 cm肿瘤亦然;阅片时需关注气胸(16.6%)和轻度放射性纤维化(48.5%)等并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Minimal invasive local therapies are alternative treatment options in patients with primary and metastatic lung malignancies being not eligible for resection. However, thermal ablations are often limited by large tumour volumes.

PURPOSE: To evaluate the efficacy and safety of CT-HDRBT in pulmonary tumours ≥4 cm compared to smaller tumours.

MATERIAL AND METHODS: In this retrospective study, 74 consecutive patients (mean age: 63 ± 12; m: 39, w: 35) with a total of 175 tumours treated in 132 interventions were enrolled between October 2003 and September 2016. Primary and assisted local tumour control (LTC), progression free survival (PFS) and overall survival (OS) after first CT-HDBRT were identified for two subgroups with tumours <4 cm (A) as well as ≥4 cm (B) using the Kaplan-Meier-Method. Radiation parameters and side effects were recorded. Log-Rank-Test and Mann-Whitney-U-Test were performed for statistical analyses with p-values <0.05 considered as significant.

RESULTS: There was no statistical difference in coverage with prescribed radiation dose (A:19.78 ± 8.62 mm (range 5-39 mm), 99.56 ± 0.99%; B:61.70 ± 21.09 mm (41-100 mm), 94.81 ± 7.19%, p = 0.263). LTC rates after 0.5-,1-,2-,3- and 5-years were higher in A compared to B (A:85%/74%/63%/60%/46%, B:71%/37%/32%/32%/32%) with longer primary (A:11months, B:5months, p = 0.003) and assisted LTC (A:9months B:20months, p = 0.339). Longer OS was observed in A (A:18.5months, B:14.5months, p = 0.011) with longer OS rates (A:96%/87%/60%/48%/19%, B:92%/73%/20%/20%/0%). Complication assessment revealed no bleedings, 16.6% pneumothoraxes and 48.5% of mild radiation fibrosis without clinical symptoms.

CONCLUSION: In conclusion, higher LTC and OS were observed in patients with primary lung malignancies <4 cm. Nevertheless, CT-HDRBT is a safe and feasible alternative even in larger tumours ≥4 cm.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Jonczyk M, Collettini F, Schnapauff D, et al. Primary and metastatic malignancies of the lung: Retrospective analysis of the CT-guided high-dose rate brachytherapy (CT-HDRBT) ablation in tumours <4 cm and ≥4 cm. Eur J Radiol. 2018. PMID: 30396661. doi:10.1016/j.ejrad.2018.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。